Skip to main content
GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · Real-Time Price · USD
69.76
-3.97 (-5.38%)
Nov 15, 2024, 12:09 PM EST - Market open

GeneDx Holdings Revenue

GeneDx Holdings had revenue of $76.87M in the quarter ending September 30, 2024, with 44.22% growth. This brings the company's revenue in the last twelve months to $267.23M, up 29.41% year-over-year. In the year 2023, GeneDx Holdings had annual revenue of $202.57M, down -13.69%.

Revenue (ttm)
$267.23M
Revenue Growth
+29.41%
P/S Ratio
7.29
Revenue / Employee
$267,228
Employees
1,000
Market Cap
1.92B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023202.57M-32.13M-13.69%
Dec 31, 2022234.69M22.50M10.60%
Dec 31, 2021212.20M32.87M18.33%
Dec 31, 2020179.32M-16.85M-8.59%
Dec 31, 2019196.17M62.83M47.12%
Dec 31, 2018 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Addus HomeCare 1.13B
Omnicell 1.06B
Amphastar Pharmaceuticals 723.55M
Supernus Pharmaceuticals 651.97M
NeoGenomics 644.12M
Beam Therapeutics 349.64M
Mirum Pharmaceuticals 307.03M
Recursion Pharmaceuticals 65.18M
Revenue Rankings

WGS News

More News